Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness. | Eur J Cancer;210: 114298, 2024 Oct. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.

Stintzing, Sebastian; Yoshino, Takayuki.

Affiliation

Stintzing S; Charité - Universitaetsmedizin Berlin, Germany. Electronic address: sebastian.stintzing@charite.de.
Yoshino T; Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Eur J Cancer ; 210: 114298, 2024 Oct.

Article in En | MEDLINE | ID: mdl-39304280

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / ErbB Receptors / Bevacizumab Limits: Adult / Humans Language: En Journal: Eur J Cancer Year: 2024 Document type: Article Country of publication: Reino Unido

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / ErbB Receptors / Bevacizumab Limits: Adult / Humans Language: En Journal: Eur J Cancer Year: 2024 Document type: Article Country of publication: Reino Unido